http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-083367-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D291-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-22 |
| filingDate | 2011-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-083367-A1 |
| titleOfInvention | QUINAZOLINONE TYPE COMPOUNDS AS CRTH ANTAGONISTS |
| abstract | Compounds, pharmaceutical composition, as well as processes to prepare these compounds. They are useful in the treatment of both chronic and acute immune allergic disorders. Claim 1: A compound for the formula (1) or a pharmaceutically acceptable salt thereof, wherein: X is a bond or -S (O) m -; And it is selected from the group consisting of: a) a bond, -O-, -NH-, -N (R9) - or -N (COR9) -; b) a remainder of formulas (2); c) a remainder of formulas (3); d) a remainder of formulas (4); and e) a remainder of formulas (5); where A is -O-, -S- or -N (R) -; B is -C-, -N-; a is 0, 1, 2 or 3; r is 0, 1 or 2; s is 0, 1 or 2; R is H, alkyl or haloalkyl; Ra is independently H, halo, alkyl or haloalkyl; Rb is independently H, halo, alkyl or haloalkyl; R1 is heteroaryl, heterocyclyl or heterocyclynyl; R2 is aryl, heteroaryl, alkyl or heterocyclyl; R3 is -C (O) OH or -N (H) -SO2-Rc; wherein Rc is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl; R4 is independently selected from the group consisting of alkyl, -OH, halo, alkoxy, haloalkoxy, -CN and haloalkyl; R8 is independently selected from the group consisting of -CN, halo, alkyl, haloalkyl, alkoxy, haloalkoxy or cycloalkyl; R9 is alkyl, haloalkyl, alkoxy, haloalkoxy or cycloalkyl; and wherein: i) the heteroaryl, heterocyclyl or heterocyclynyl group in R1; and ii) each of the aryl, heteroaryl, alkyl or heterocyclyl groups of R2; they are unsubstituted or independently substituted with 1 to 5 R5 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclynyl, aryl, heteroaryl, halo, -CN, -SF5, -OSF5, - NO2, -CH2OSi (R14) (R15) (R16), -OR14, -C (O) R14, -C (O) OR14, -OC (O) -R14, -OC (O) N (R14) (R15 ), -C (O) N (R14) (R15), -S (O) mR14, -S (O) pN (R14) (R15), - C (= NOR14) R15, -N (R14) (R15 ), -N (R14) C (O) R15, -N (R14) S (O) pR15, -N (R14) S (O) pN (R15) (R16), -N (R14) C (O) N (R15) (R16) and -N (R14) C (O) OR16; or when a position is disubstituted with two R5 groups, the two R5 groups can form a cycloalkyl or heterocyclyl ring that is unsubstituted or substituted with 1 to 5 R6 groups and in which each of the alkyl, alkenyl, alkynyl groups , cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclynyl, aryl, heteroaryl in R5 are unsubstituted or independently substituted with 1 to 5 R6 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclynyl, aryl, heteroaryl, halo, -CN, -SF5, -OSF5, -NO2, -CH2OSi (R14) (R15) (R16), -OR14, -C (O) R14, -C (O) OR14, -OC (O) -R14, -OC (O) N (R14) (R15), -C (O) N (R14) (R15), -S (O) mR14, -S (O) pN (R14) (R15), - C (= NOR14) R15, -N (R14) (R15), -N (R14) C (O) R15, -N (R14) S (O) pR15, -N (R14) S (O) pN (R15 ) (R16), -N (R14) C (O) N (R15) (R16) and -N (R14) C (O) OR16; and wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclynyl, aryl, heteroaryl groups in R6 are unsubstituted or independently substituted with 1 to 5 R7 groups independently selected from the group consisting of alkyl, alkenyl , alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclynyl, aryl, heteroaryl, halo, -CN, -SF5, -OSF5, -NO2, -CH2OSi (R14) (R15) (R16), -OR14, -C (O) R14 , -C (O) OR14, -OC (O) -R14, -OC (O) N (R14) (R15), -C (O) N (R14) (R15), -S (O) mR14, - S (O) pN (R14) (R15), -C (= NOR14) R15, -N (R14) (R15), -N (R14) C (O) R15, -N (R14) S (O) pR15 , -N (R14) S (O) pN (R15) (R16), -N (R14) C (O) N (R15) (R16) and -N (R14) C (O) OR16; wherein R14, R15 and R16 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclynyl, aryl, heteroaryl, R17-alkyl, R17-alkenyl, R17-alkynyl, R17 -cycloalkyl, R17-cycloalkenyl, R17-heterocyclyl, R17-heterocyclynyl, R17-aryl and R17-heteroaryl; R17 is 1-5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclynyl, aryl, aryl substituted with halo, aryl substituted with nitrile, aryl substituted with phenyl, heteroaryl, halo, - CN, -SF5, -OSF5, -NO2, heteroaryl, haloalkyl, -C (O) R18, -C (O) OH, -C (O) OR18, -C (O) NHR19, -C (O) NH2, -C (O) N (R18) (R19), -S (O) mR18, -S (O) pNH2, -S (O) pNH (alkyl), -S (O) pN (alkyl) (alkyl), -S (O) pNH (aryl), -S (O) 2NHR19, -S (O) 2NH (heterocycloalkyl), -S (O) 2N (alkyl) (aryl), haloalkoxy, -OH, -OR19, -O -heterocycloalkyl, -O-cycloalkylalkyl, -O-heterocyclylalkyl, -NH2, -NHR19, -N (alkyl) 2, -N (arylalkyl) 2, -N (arylalkyl) - (heteroarylalkyl), -NHC (O) R19, -NHC (O) NH2, -NHC (O) NH (alkyl), -NHC (O) N (alkyl) (alkyl), -N (alkyl) C (O) NH (alkyl), -N (alkyl) C (O) N (alkyl) (alkyl), -NHS (O) 2R21, -NHS (O) 2NH (alkyl), -NHS (O) 2N (alkyl) (alkyl), -N (alkyl) S (O) 2NH (alkyl) and -N (alkyl) S (O) 2N (alkyl) (alkyl); R18 is alkyl, cycloalkyl, aryl, arylalkyl or heteroarylalkyl; R19 is alkyl, cycloalkyl, aryl, aryl substituted with halo, arylalkyl, heteroaryl or heteroarylalkyl; R21 is alkyl, cycloalkyl, aryl, aryl substituted with halo, arylalkyl, heteroaryl or heteroarylalkyl; b is 0, 1 or 2, n is an integer from 1 to 5; m is independently an integer from 0 to 2; p is an integer from 1 to 2; and q is an integer from 0 to 5. |
| priorityDate | 2010-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.